Cardioprotective effects of Qishen Granule (芪参颗粒) on sarcoplasmic reticulum Ca2+ handling in heart failure rats

Ling-hui Lu; Chun Li; Qi-yan Wang; Qian Zhang; Yi Zhang; Hui Meng; Yong Wang; Wei Wang

doi:10.1007/s11655-017-2809-x

Your Location：

Home >

Browse articles >

Cardioprotective effects of Qishen Granule (芪参颗粒) on sarcoplasmic reticulum Ca2+ handling in heart failure rats

Updated：2021-08-27

- Cardioprotective effects of Qishen Granule (芪参颗粒) on sarcoplasmic reticulum Ca2+ handling in heart failure rats
- Chinese Journal of Integrative Medicine Vol. 23, Issue 7, Pages: 510-517(2017)
- Affiliations：
  
  1. School of Preclinical Medicine, Beijing University of Chinese Medicine,Beijing,China
  2. Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine,Beijing,China
  3. School of Life Sciences, Beijing University of Chinese Medicine,Beijing,China
  4. School of Chinese Materia Medica, Beijing University of Chinese Medicine,Beijing,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81530100, 81470191, and 81302908)
- DOI：10.1007/s11655-017-2809-x
  CLC：
- Published：2017，
  
  Published Online：11 May 2017，
Scan for full text
Lu, Lh., Li, C., Wang, Qy. et al. Cardioprotective effects of Qishen Granule (芪参颗粒) on sarcoplasmic reticulum Ca2+ handling in heart failure rats., Chin. J. Integr. Med. 23, 510–517 (2017). https://doi.org/10.1007/s11655-017-2809-x

Ling-hui Lu, Chun Li, Qi-yan Wang, et al. Cardioprotective effects of Qishen Granule (芪参颗粒) on sarcoplasmic reticulum Ca2+ handling in heart failure rats. [J]. Chinese Journal of Integrative Medicine 23(7):510-517(2017)
Lu, Lh., Li, C., Wang, Qy. et al. Cardioprotective effects of Qishen Granule (芪参颗粒) on sarcoplasmic reticulum Ca2+ handling in heart failure rats., Chin. J. Integr. Med. 23, 510–517 (2017). https://doi.org/10.1007/s11655-017-2809-x DOI：

Ling-hui Lu, Chun Li, Qi-yan Wang, et al. Cardioprotective effects of Qishen Granule (芪参颗粒) on sarcoplasmic reticulum Ca2+ handling in heart failure rats. [J]. Chinese Journal of Integrative Medicine 23(7):510-517(2017) DOI： 10.1007/s11655-017-2809-x.

摘要

To assess the effects of Qishen Granule (芪参颗粒

QSG) on sarcoplasmic reticulum (SR) Ca2+ handling in heart failure (HF) model of rats and to explore the underlying molecular mechanisms. HF rat models were induced by left anterior descending coronary artery ligation surgery and high-fat diet feeding. Rats were randomly divided into sham (n=10)

model (n=10)

QSG (n=12

2.2 g/kg daily) and metoprolol groups (n=12

10.5 mg/kg daily). The therapeutic effects of QSG were evaluated by echocardiography and blood lipid testing. Intracellular Ca2+ concentration and sarco-endoplasmic reticulum ATPase 2a (SERCA2a) activity were detected by specifific assay kits. Expressions of the critical regulators in SR Ca2+ handling were evaluated by Western blot and real-time quantitative polymerase chain reaction. HF model of rats developed ventricular remodeling accompanied with calcium overload and defective Ca2+ release-uptake cycling in cardiomyocytes. Treatment with QSG improved contractive function

attenuated ventricular remodeling and reduced the basal intracellular Ca2+ level. QSG prevented defective Ca2+ leak by attenuating hyperphosphorylation of ryanodine receptor 2

inhibiting expression of protein kinase A and up-regulating transcriptional expression of protein phosphatase 1. QSG also restored Ca2+ uptake by up-regulating expression and activity of SERCA2a and promoting phosphorylation of phospholamban. QSG restored SR Ca2+ cycling in HF rats and served as an ideal alternative drug for treating HF.

Abstract

To assess the effects of Qishen Granule (芪参颗粒

model (n=10)

QSG (n=12

2.2 g/kg daily) and metoprolol groups (n=12

attenuated ventricular remodeling and reduced the basal intracellular Ca2+ level. QSG prevented defective Ca2+ leak by attenuating hyperphosphorylation of ryanodine receptor 2

关键词

Qishen GranuleCa2+ handlingheart failureryanodine receptor 2sarco-endoplasmic reticulum ATPase 2aChinese Medicine

Keywords

Qishen GranuleCa2+ handlingheart failureryanodine receptor 2sarco-endoplasmic reticulum ATPase 2aChinese Medicine

references

Basra SS, Virani SS, Paniagua D, Kar B, Jneid H. Acute coronary syndrome: unstable angina and non-ST elevation myocardial infarction. Heart Fail Clin 2016;12:31–48.

Heggermont WA, Papageorgiou AP, Heymans S, van Bilsen M. Metabolic support for the heart: complementary therapy for heart failure? Eur J Heart Fail 2016;18:1420–1429.

Xanthakis V, Enserro D, Larson MG, Wollert K, Januzzi J, Quiroz R, et al. Prevalence, neurohormonal correlates and prognosis of heart failure stages in the community. JACC Heart Fail 2016;4:808–815.

Lompré AM, Hajjar RJ, Harding SE, Kranias EG, Lohse MJ, Marks AR. Ca2+ cycling and new therapeutic approaches for heart failure. Circulation 2010;121:822–830.

Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest 2013;123:46–52.

Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Advanc Pharmacol 2010;59:1–30.

Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proceed Nat Acad Sci 2006;103:511–518.

Oort RJV, Mccauley MD, Dixit SS, Pereira L, Yang Y, Respress JL, et al. Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation 2010;122:2669–2679.

Park WJ, Oh JG. SERCA2a: a prime target for modulation of cardiac contractility during heart failure. Bmb Reports 2013;46:237–243.

Shareef MA, Anwer LA, Poizat C. Cardiac SERCA2A/B: therapeutic targets for heart failure. Eur J Pharmacol 2014;724:1–8.

Maclennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nature Rev Molec Cell Biol 2003;4:566–577.

Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Meli AC, Wronska A, et al. Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. J Clin Invest 2010;120:4375–4387.

Reiken S, Gaburjakova M, Gaburjakova J, He KK, Prieto A, Becker E, et al. Beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 2001;104:2843–2848.

Tuncay E, Zeydanli EN, Turan B. Cardioprotective effect of propranolol on diabetes-induced altered intracellular Ca2+ signaling in rat. J Bioenerget Biomembr 2011;43:747–756.

Michal M, Urszula M. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the postinfarction rat heart. Cardiovasc Res 2008;79:42–51.

Dube P, Weber KT. Congestive heart failure: pathophysiologic consequences of neurohormonal activation and the potential for recovery: part II. Am J Med Sci 2011;342:503–506.

Lee HY, Baek SH. Optimal use of beta-blockers for congestive heart failure. Circulat J 2016;80:565–571.

Pellicori P, Cleland JG, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P, et al. Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther 2016;30:599–609.

Tang WH, Huang Y. Cardiotonic modulation in heart failure: insights from traditional Chinese medicine. J Am Coll Cardiol 2013;62:1073–1074.

Shang H, Zhang J, Yao C, Liu B, Gao X, Ren M, et al. Qi-shen-yi-qi Dripping Pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Altern Med 2013;2013:738391.

Xian S, Yang Z, Lee J, Jiang Z, Ye X, Luo L, et al. A randomized, double-blind, multicenter, placebo-controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure. J Ethnopharmacol 2016;186:136–142.

Wang Y, Li C, Ouyang Y, Yu J, Guo S, Liu Z, et al. Cardioprotective effects of Qishenyiqi mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin-converting enzyme 2. Evid Based Complement Altern Med 2012;2012:978127.

Li C, Wang Y, Qiu Q, Shi T, Wu Y, Han J, et al. Qishenyiqi protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-κB signaling pathway. PLos One 2014;9:e104255.

Li C, Wang J, Wang Q, Zhang Y, Zhang N, Lu L, et al. Qishen granules inhibit myocardial inflammation injury through regulating arachidonic acid metabolism. Sci Rep 2016;6:36949.

Wang Y, Liu Z, Li C, Li D, Ouyang Y, Yu J, et al. Drug target prediction based on the herbs components: the study onthe multitargets pharmacological mechanism of Qishenkeli acting on the coronary heart disease. Evid Based Complement Altern Med 2012;2012:698531.

Lu L, Wang J, Cao Y, Zhang Q, Li C, Wu Y, et al. Establishment and evaluation of disease and syndrome integrated animal model on coronary heart disease complicated with hyperlipemia. China J Tradit Chin Med Pharm (Chin) 2016;31:1816–1821.

Mohamed AR, El-Hadidy WF, Mannaa HF. Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats. Drugs R D 2014;14:233–239.

Berthiaume JM, Young ME, Chen X, Mcelfresh TA, Yu X, Chandler MP. Normalizing the metabolic phenotype after myocardial infarction: impact of subchronic high fat feeding. J Mol Cell Cardiol 2012;53:125–133.

Luo L, Chen J, Guo S, Wang J, Gao K, Zhang P, et al. Chinese herbal medicine in the treatment of chronic heart failure: three-stage study protocol for a randomized controlled trial. Evid Based Complement Altern Med 2015;2015:927160.

Santulli G, Xie W, Reiken SR, Marks AR. Mitochondrial calcium overload is a key determinant in heart failure. Proc Nat Acad Sci USA 2015;112:11389–11394.

Schultz JEJ, Glascock BJ, Witt SA, Nieman ML, Nattamai KJ, Liu LH, et al. Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am J Physiol Heart Circulat Physiol 2004;286:H1146–H1153.

Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011;124:304–313.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

The mobilization of autologous bone marrow stem cells in the treatment of heart failure with Chinese medicine

Insights of Chinese medicine on ventricular remodeling: Multiple-targets, individualized-treatment

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Related Author

No data

Related Institution

Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Beijing University of Chinese Medicine

AMI Key Laboratory of Chinese Medicine in Guangzhou, Intensive Care Research Team of Traditional Chinese Medicine, Guangdong Province Hospital of Chinese Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Science

Georg-August-Universität Göttingen, Göttingen

The Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics’ Ministry of Public Health

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰